Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placental transfer of certolizumab pegol in pregnant women receiving Cimzia
NL-OMON40792Active, not recruiting
- Sponsor
- UCB
- Start
- Jan 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of certolizumab pegol in autoimmune disease, rheumatism, rheumatoid arthritis (RA) and 1 more, sponsored by UCB. Primary endpoint: Plasma concentration of certolizumab pegol in the infant at birth. Started Jan 2015; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
autoimmune diseaserheumatismrheumatoid arthritis (RA)Crohn's disease
Beyond the preview
Go deeper on NL-OMON40792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40792.